Cambrex Corporation (NYSE:CBM) – Analysts at First Analysis cut their Q4 2017 EPS estimates for Cambrex Corporation in a research report issued on Monday. First Analysis analyst S. Schwartz now anticipates that the biotechnology company will post earnings of $1.11 per share for the quarter, down from their prior estimate of $1.18. First Analysis also issued estimates for Cambrex Corporation’s Q1 2018 earnings at $0.47 EPS, Q3 2018 earnings at $0.56 EPS and FY2018 earnings at $2.90 EPS.

Cambrex Corporation (NYSE:CBM) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.08. Cambrex Corporation had a return on equity of 23.42% and a net margin of 18.79%. The company had revenue of $112.60 million during the quarter, compared to analyst estimates of $108.44 million. During the same quarter last year, the firm posted $0.47 EPS. The firm’s revenue for the quarter was up 13.4% on a year-over-year basis.

COPYRIGHT VIOLATION NOTICE: “Q4 2017 EPS Estimates for Cambrex Corporation Lowered by First Analysis (CBM)” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/11/16/q4-2017-eps-estimates-for-cambrex-corporation-lowered-by-first-analysis-cbm.html.

Other equities research analysts have also issued research reports about the company. BidaskClub raised Cambrex Corporation from a “hold” rating to a “buy” rating in a report on Friday, August 4th. Craig Hallum reaffirmed a “buy” rating and set a $60.00 target price (down previously from $70.00) on shares of Cambrex Corporation in a report on Tuesday, October 31st. Finally, ValuEngine raised Cambrex Corporation from a “hold” rating to a “buy” rating in a report on Tuesday, August 22nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $62.33.

Shares of Cambrex Corporation (CBM) traded up $1.85 on Wednesday, reaching $47.35. The company had a trading volume of 525,300 shares, compared to its average volume of 333,237. Cambrex Corporation has a 52 week low of $42.55 and a 52 week high of $62.95. The stock has a market cap of $1,491.38, a price-to-earnings ratio of 14.35 and a beta of 2.26.

In related news, CEO Steven M. Klosk sold 12,000 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $51.53, for a total value of $618,360.00. Following the completion of the sale, the chief executive officer now owns 95,328 shares in the company, valued at approximately $4,912,251.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Steven M. Klosk sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $54.96, for a total value of $219,840.00. Following the completion of the sale, the chief executive officer now owns 87,328 shares of the company’s stock, valued at approximately $4,799,546.88. The disclosure for this sale can be found here. Company insiders own 2.48% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. Creative Planning lifted its position in Cambrex Corporation by 162.6% in the second quarter. Creative Planning now owns 1,765 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 1,093 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in shares of Cambrex Corporation by 9.3% during the second quarter. Nisa Investment Advisors LLC now owns 1,760 shares of the biotechnology company’s stock valued at $105,000 after buying an additional 150 shares during the period. YorkBridge Wealth Partners LLC increased its stake in shares of Cambrex Corporation by 5.2% during the second quarter. YorkBridge Wealth Partners LLC now owns 1,971 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 97 shares during the period. Riverhead Capital Management LLC increased its stake in shares of Cambrex Corporation by 90.3% during the second quarter. Riverhead Capital Management LLC now owns 2,664 shares of the biotechnology company’s stock valued at $159,000 after buying an additional 1,264 shares during the period. Finally, Advisor Group Inc. increased its stake in shares of Cambrex Corporation by 29.8% during the second quarter. Advisor Group Inc. now owns 2,681 shares of the biotechnology company’s stock valued at $160,000 after buying an additional 615 shares during the period.

Cambrex Corporation Company Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Earnings History and Estimates for Cambrex Corporation (NYSE:CBM)

Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.